West Pharmaceutical Services, Inc.

NYSE WST

West Pharmaceutical Services, Inc. EBT Margin for the Trailing 12 Months (TTM) ending September 30, 2024: 20.47%

West Pharmaceutical Services, Inc. EBT Margin is 20.47% for the Trailing 12 Months (TTM) ending September 30, 2024, a -9.02% change year over year. EBT Ratio (Earnings Before Tax Ratio) is the fraction of earnings before taxes to total revenue, indicating the company's profitability before the impact of tax expenses.
  • West Pharmaceutical Services, Inc. EBT Margin for the Trailing 12 Months (TTM) ending September 30, 2023 was 22.50%, a -10.71% change year over year.
  • West Pharmaceutical Services, Inc. EBT Margin for the Trailing 12 Months (TTM) ending September 30, 2022 was 25.20%, a -0.95% change year over year.
  • West Pharmaceutical Services, Inc. EBT Margin for the Trailing 12 Months (TTM) ending September 30, 2021 was 25.44%, a 42.55% change year over year.
  • West Pharmaceutical Services, Inc. EBT Margin for the Trailing 12 Months (TTM) ending September 30, 2020 was 17.85%, a 14.13% change year over year.
Key data
Date EBT Margin Net Income Margin EBITDA Margin EBIT Margin
Market news
Loading...
NYSE: WST

West Pharmaceutical Services, Inc.

CEO Mr. Eric M. Green
IPO Date March 17, 1980
Location United States
Headquarters 530 Herman O. West Drive
Employees 10,600
Sector Health Care
Industries
Description

West Pharmaceutical Services, Inc. designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Proprietary Products and Contract-Manufactured Products. The Proprietary Products segment offers stoppers and seals for injectable packaging systems; syringe and cartridge components, including custom solutions for the needs of injectable drug applications, as well as administration systems that enhance the safe delivery of drugs through advanced reconstitution, mixing, and transfer technologies; and films, coatings, washing, and vision inspection and sterilization processes and services to enhance the quality of packaging components. It also provides drug containment solutions, including Crystal Zenith, a cyclic olefin polymer in the form of vials, syringes, and cartridges; and self-injection devices, as well as a range of integrated solutions, including analytical lab services, pre-approval primary packaging support and engineering development, regulatory expertise, and after-sales technical support. This segment serves biologic, generic, and pharmaceutical drug companies. The Contract-Manufactured Products segment is involved in the design, manufacture, and automated assembly of devices used in surgical, diagnostic, ophthalmic, injectable, and other drug delivery systems, as well as consumer products. It serves pharmaceutical, diagnostic, and medical device companies. The company distributes its products through its sales force and distribution network, as well as contract sales agents and regional distributors. West Pharmaceutical Services, Inc. was incorporated in 1923 and is headquartered in Exton, Pennsylvania.

Similar companies

HAE

Haemonetics Corporation

USD 79.96

0.69%

RGEN

Repligen Corporation

USD 156.55

-1.19%

COO

The Cooper Companies, Inc.

USD 89.11

-2.38%

TFX

Teleflex Incorporated

USD 179.17

0.35%

EMBC

Embecta Corp.

USD 20.10

0.95%

BDX

Becton, Dickinson and Company

USD 235.80

-0.17%

RMD

ResMed Inc.

USD 228.83

-0.62%

MMSI

Merit Medical Systems, Inc.

USD 99.89

4.44%

ICUI

ICU Medical, Inc.

USD 161.08

1.85%

HOLX

Hologic, Inc.

USD 70.20

-0.13%

BAX

Baxter International Inc.

USD 30.62

0.39%

StockViz Staff

January 15, 2025

Any question? Send us an email